Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. ANCHOR was a 12-week, phase 3 study that evaluated the efficacy and...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular diabetology 2013-07, Vol.12 (1), p.100-100
Main Authors: Brinton, Eliot A, Ballantyne, Christie M, Bays, Harold E, Kastelein, John J, Braeckman, Rene A, Soni, Paresh N
Format: Article
Language:English
Subjects:
Biomarkers - blood
Cardiovascular disease
Cholesterol
Cholesterol, LDL - blood
Diabetes
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - diagnosis
Diabetes Mellitus, Type 2 - drug therapy
Double-Blind Method
Dyslipidemias - blood
Dyslipidemias - diagnosis
Dyslipidemias - drug therapy
Eicosapentaenoic Acid - analogs & derivatives
Eicosapentaenoic Acid - therapeutic use
Glycated Hemoglobin A - metabolism
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypoglycemic Agents - therapeutic use
Hypolipidemic Agents - therapeutic use
Inflammation Mediators - blood
Lipids
Original Investigation
Statins
Time Factors
Treatment Outcome
Triglycerides - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. ANCHOR was a 12-week, phase 3 study that evaluated the efficacy and safety of IPE in patients (N = 702) with residual high fasting TG levels (≥200 and
ISSN:1475-2840
1475-2840
DOI:10.1186/1475-2840-12-100